Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Innovation (N Y) ; 1(3): 100046, 2020 Nov 25.
Article in English | MEDLINE | ID: covidwho-1164617

ABSTRACT

[This corrects the article DOI: 10.1016/j.xinn.2020.100028.].

2.
Innovation (N Y) ; 1(2): 100028, 2020 08 28.
Article in English | MEDLINE | ID: covidwho-720752

ABSTRACT

Since the outbreak of COVID-19, many randomized controlled trials have been launched to test the efficacy of promising treatments. These trials will offer great promise for future treatment. However, a public health emergency calls for a balance between gathering sound evidence and granting therapeutic access to promising trial drugs as widely as possible. In an electronic survey, we found that 3.9% of the participants preferred to receive an unproven trial drug directly in the hypothetical scenario of mild COVID-19 infection. This percentage increased drastically to 31.1% and 54.2% in the hypothetical scenario of severe and extremely severe infection, respectively. Our survey indicates a likelihood of substantial receptivity of trial drugs among actual patients in severe conditions. From the perspective of deontological ethics, a trial can only be approved when potential benefits of the investigational treatment are presumed to outweigh risks, so compassionate or off-label use of investigational therapies merits evaluation.

SELECTION OF CITATIONS
SEARCH DETAIL